

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**PATENT TRIAL AND APPEAL BOARD**

---

ADAMIS PHARMACEUTICALS CORPORATION  
Petitioner

v.

BELCHER PHARMACEUTICALS, LLC  
Patent Owner

---

CASE: IPR2019-01021  
U.S. PATENT NO. 9,283,197

---

**PETITIONER'S UPDATED MANDATORY NOTICE TO NOTIFY BOARD  
OF DISTRICT COURT'S SUPPLEMENTAL CLAIM CONSTRUCTION**

**Mail Stop PATENT BOARD**  
Patent Trial and Appeal Board  
United States Patent and Trademark Office  
PO Box 1450  
Alexandria, Virginia 22313-1450

### Exhibits Filed by Petitioner

- Ex. 1001: U.S. Patent No. 9,283,197 (“197 Patent”), filed August 15, 2014, issued March 15, 2016
- Ex. 1002: Declaration of James Kipp, Ph.D.
- Ex. 1003: *Curriculum vitae* of James Kipp, Ph.D.
- Ex. 1004: Prosecution History of U.S. Patent No. 9,283,197
- Ex. 1005: Stepensky, D., *Long-Term Stability Study of L-Adrenaline Injections: Kinetics of Sulfonation and Racemization Pathways of Drug Degradation*, Journal of Pharmaceutical Sciences, Vol. 93 No. 4 (“Stepensky”), published in April 2004
- Ex. 1006: U.S. Patent Application Publication No. 2008/0269347 to Bruss et al. (“Bruss”)
- Ex. 1007: Fyllingen, G., *Racemisation and oxidation in adrenaline injections*, Acta Pharm. Nord. 2(5) (“Fyllingen”), published in 1990
- Ex. 1008: Vidal-Ollivier, E., *Assay for epinephrine and its impurities using reversed-phase high-performance liquid chromatography*, Journal of Chromatography (“Vidal”), published in 1987
- Ex. 1009: Kerddonfak, S., *The Stability and Sterility of Epinephrine Prefilled Syringe*, Asian Pacific Journal of Allergy and Immunology, (“Kerddonfak”), published in 2010

- Ex. 1010: U.S. Patent No. 5,002,973 to Zeleznick et al. (“*Zeleznick*”)
- Ex. 1011: International Patent Publication No. WO 2014/127015 to Gupta et al. (“*Gupta*”).
- Ex. 1012: Connors, K.A., *Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists*, 2nd Edition (“*Connors*”), published in 1986
- Ex. 1013: 2004 United States Pharmacopeia Monograph for Epinephrine (“*2004 USP*”)
- Ex. 1014: 2014 United States Pharmacopeia Monograph for Epinephrine (“*2009 USP*” or “*USP*”)
- Ex. 1015: 2014 United States Pharmacopeia Monograph for Epinephrine (“*2014 USP*”)
- Ex. 1016: Szulczewski, D. et al., *Analytical Profiles of Drug Substances*, 7, Epinephrine (“*Szulczewski*”), published in 1978
- Ex. 1017: Moed H.D. et al., *Synthesis of beta-phenyl-ethylamine derivatives III Bronchodilators*. *Rec. Trav. Chim.* 74 (“*Moed*”), published in 1955
- Ex. 1018: IMS Product Information
- Ex. 1019: Claim Construction Order in Case No. 17-775-LPS, *Belcher Pharmaceuticals, LLC v. Hospira, Inc.*

- Ex. 1020: Belcher Initial Infringement Contentions in Case No. 8:18-cv-02379-WFJ-AAS, *Adamis Pharmaceuticals Corp. v. Belcher Pharmaceuticals, LLC*
- Ex. 1021: U.S. Patent Application Publication No. 12/846,656 to MacKay (“MacKay”)
- Ex. 1022: Goodman, L.S., *The Pharmacological Basis of Therapeutics*, 5<sup>th</sup> Edition, (“Goodman”) published in 1975
- Ex. 1023: Belcher Expert Report in Case No. 17-775-LPS, *Belcher Pharmaceuticals, LLC v. Hospira, Inc.*
- Ex. 1024: Order regarding supplemental claim construction in Case No. 17-775-LPS, *Belcher Pharmaceuticals, LLC v. Hospira, Inc.*
- Ex. 1025: Memorandum Opinion regarding supplemental claim construction in Case No. 17-775-LPS, *Belcher Pharmaceuticals, LLC v. Hospira, Inc.*

Pursuant to 37 C.F.R. §§ 42.8(a)(3) and 42.8(b)(2), Petitioner Adamis Pharmaceuticals Corporation hereby updates its mandatory notice concerning Related Matters.

On May 30, 2019, the district court in related case No. 17-775-LPS, issued a supplemental claim construction Order construing the following terms from U.S. Patent No. 9,283,197:

<b>Claim Term</b>	<b>Court's Construction</b>
<b>said liquid formulation having a pH between 2.8 and 3.3</b> [claim 6 of the '197 Patent]	Refers to pH of final product
<b>compounded in an aqueous solution as 1.0 to 1.06 mg/mL l-epinephrine</b> [claim 6 of the '197 Patent]	Product-by-process limitation

(Ex. 1024; *see also* Ex. 1025 at 2 and 4). On June 11, 2019, the District Court unsealed the Memorandum Opinion regarding supplemental claim construction, which is submitted as Exhibit 1025.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.